Zheng Quan Shi Bao Wang·2025-07-16 08:56Core Viewpoint - The generic drug consistency evaluation concept has shown a significant increase, with a rise of 2.67%, making it the second-highest gaining sector on the market as of July 16 [1][2]. Market Performance - The generic drug consistency evaluation sector saw 119 stocks increase in value, with notable performers including: - Guangsheng Tang, which rose by 16.55% - Lai Mei Pharmaceutical, which increased by 8.48% - Han Yu Pharmaceutical, which gained 6.41% [1][2]. - Conversely, the sector also experienced declines, with *ST Su Wu dropping by 5.02%, Nanxin Pharmaceutical by 3.17%, and Kelun Pharmaceutical by 0.95% [1]. Capital Flow - The sector attracted a net inflow of 2.102 billion yuan from major funds, with 77 stocks receiving net inflows. Five stocks had net inflows exceeding 100 million yuan, led by Qianhong Pharmaceutical with 227 million yuan [2][3]. - Other significant net inflows were observed in: - Han Yu Pharmaceutical with 166 million yuan - Ha San Lian with 155 million yuan - Run Du Shares with 145 million yuan [2]. Stock Performance Metrics - The top stocks in terms of net inflow ratio included: - Run Du Shares at 42.20% - Ha San Lian at 34.99% - Zhejiang Zhen Yuan at 29.25% [3]. - The performance of stocks within the sector varied, with Qianhong Pharmaceutical showing a daily increase of 9.98% and a turnover rate of 14.39% [3][4].